Business Context and Reporting Period
This Form 8-K was filed by NantKwest, Inc. on May 22, 2020, reporting a material definitive agreement entered into on the same date. The filing details a strategic collaboration with ImmunityBio, Inc., an affiliate of NantKwest, focused on the joint development, manufacturing, and marketing of therapeutics and vaccines targeting SARS-CoV-2 (COVID-19).
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on the terms of a new strategic partnership.
Material Changes and Agreement Terms
The primary material change is the execution of a binding term sheet for a collaborative effort. Key terms include:
- Scope: Joint development of haNK, mesenchymal stem cells (MSC), adenovirus constructs (Ad5), and N-803 (a novel IL-15 cytokine superagonist).
- Contributions: NantKwest contributes haNK, MSC, and manufacturing capabilities. ImmunityBio contributes Ad5, N-803, and equipment.
- Cost Sharing: All costs related to global development, manufacturing, and marketing are shared equally.
- Profit Sharing: Global net profits from individual products are split 60% to the contributing party and 40% to the other. Profits from combined collaboration products are shared equally.
- Governance: The collaboration will be supervised by joint committees with equal representation from both parties.
Outlook, Risks, and Contingencies
The parties expect to finalize a more detailed agreement in the near future to memorialize the material terms. The binding term sheet is intended to be filed as an exhibit to NantKwest's Quarterly Report on Form 10-Q for the period ended June 30, 2020, or replaced by the final agreement if executed prior to that filing. The filing notes that the description of the term sheet is not complete and is subject to the full text of the agreement.
Investor Verification Checklist
- Verify the finalization status of the detailed agreement referenced in the term sheet.
- Review the full text of the binding term sheet when filed as an exhibit to the Form 10-Q for the period ended June 30, 2020.
- Confirm the specific regulatory pathways and timelines for the development of the four product candidates (haNK, MSC, Ad5, N-803).
- Assess the financial impact of the equal cost-sharing arrangement on NantKwest's cash burn rate.